Long-Term Gender-Affirming Hormone Therapy and Cognitive Functioning in Older Transgender Women Compared With Cisgender Women and Men

被引:13
|
作者
van Heesewijk, Jason O. [1 ,2 ]
Dreijerink, Koen M. A. [1 ,2 ]
Wiepjes, Chantal M. [1 ,2 ]
Kok, Almar A. L. [3 ]
van Schoor, Natasja M. [3 ]
Huisman, Martijn [3 ]
den Heijer, Martin [1 ,2 ]
Kreukels, Baudewijntje P. C. [4 ]
机构
[1] Amsterdam Univ Med Ctr, Dept Endocrinol, Locat VUmc, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[2] Amsterdam Univ Med Ctr, Ctr Expertise Gender Dysphoria, Locat VUmc, Amsterdam, Netherlands
[3] Amsterdam Univ Med Ctr, Dept Epidemiol & Data Sci, Locat VUmc, Amsterdam, Netherlands
[4] Amsterdam Univ Med Ctr, Dept Med Psychol, Locat VUmc, Amsterdam, Netherlands
关键词
Gender Dysphoria; Older Transgender Women; Gender-Affirming Hormone Therapy; Cognitive Functioning; Cardiovascular Risk; Psychological Functioning; BREAST-CANCER; ENDOCRINE TREATMENT; HEALTH; RISK; ESTRADIOL; PEOPLE; AGE;
D O I
10.1016/j.jsxm.2021.05.013
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Long-term gender-affirming hormone therapy (GHT) in older transgender individuals could have beneficial effects on cognitive functioning. Cardiovascular risk factors and psychological factors are known determinants of cognition. Despite the rising number of older transgender individuals, only few studies have examined cognitive functioning in this population. Aim: We aimed to assess differences in cognitive functioning between transgender women, and non-transgender (cisgender) women and men, and investigated the contribution of cardiovascular risk factors and psychological factors on these differences. Methods: In this study, 37 transgender women (age range 55 to 69) receiving GHT for at least ten years (range 10.2 to 41.6) were examined, and their cognitive functioning was compared to an age and education level matched cohort consisting of 222 cisgender women and men from the Longitudinal Aging Study Amsterdam. Linear regression analyses were performed. Outcomes: Cognitive functioning was assessed by neuropsychological tests including Mini-Mental State Examination (MMSE), Category Fluency animals, Letter Fluency D, 15-Word test (15WT) immediate and delayed recall. Additionally, cardiovascular risk factors and psychological factors such as cardiovascular disease, hypertension, antihypertensive use, statin use, diabetes mellitus, overweight, smoking, alcohol consumption, psychophar-maceutical use, anxiety and depression symptoms were collected. Results: Transgender women had higher MMSE scores compared with cisgender women (+0.9, 95% CI 0.4 to 1.5), and cisgender men (+1.1, 95% CI 0.4 to 1.8). On all other tests transgender women performed similar to cisgender men. Transgender women performed at a lower level than cisgender women on 15WT immediate recall,-5.5, 95% CI-7.6 to -3.4, and 15WT delayed recall,-2.7, 95% CI-3.7 to-1.7, and equal to cisgender women on Fluency animals and Fluency D. Cardiovascular and psychological factors (i.e., cardiovascular disease and depression symptoms) partly explained differences on MMSE score between transgender women and cisgen-der-control groups. Clinical Implications: The results of this study do not indicate a need for tailored hormone treatment strategies for older transgender women, based on cognitive aspects after long-term GHT. Strengths & Limitations: As one of the first studies, this study compared older transgender women to a large cohort of cisgender men and women regarding cognitive functioning and took into account numerous potential influencing factors. Limitations include difference in test procedures and the cross-sectional design of the study. Conclusion: Cognitive differences between transgender women and cisgender women and men were small, albeit significant. This may suggest that long-term GHT effects on cognitive functioning in older transgender women are minimal. (C) 2021 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
引用
收藏
页码:1434 / 1443
页数:10
相关论文
共 50 条
  • [41] Considerations in gender-affirming hormone therapy in transgender and gender diverse patients undergoing liver transplantation
    Nikzad, Newsha
    Fisher, Andrew R.
    Pillai, Anjana
    Targownik, Laura E.
    Te, Helen S.
    Aronsohn, Andrew
    Paul, Sonali
    AMERICAN JOURNAL OF TRANSPLANTATION, 2024, 24 (09) : 1567 - 1572
  • [42] Breast cancer and gender-affirming hormone therapy for transgender and gender-diverse (TGD) individuals
    -Rake, Elizabeth J. Cathcart
    Ruddy, Kathryn J.
    Tevaarwerk, Amye J.
    Jatoi, Aminah
    MATURITAS, 2024, 181
  • [43] Effects of Estradiol Therapy on Resting-State Functional Connectivity of Transgender Women After Gender-Affirming Related Gonadectomy
    Schneider, Maiko A.
    Spritzer, Poll M.
    Minuzzi, Luciano
    Frey, Benicio N.
    Syan, Sabrina K.
    Fighera, Tayane M.
    Schwarz, Karine
    Costa, Angelo B.
    da Silva, Dhiordan C.
    Garcia, Claudia C. G.
    Fontanarils, Anna M., V
    Real, Andre G.
    Anes, Mauricio
    Castan, Juliana U.
    Cunegatto, Fernanda R.
    Lobato, Maria I. R.
    FRONTIERS IN NEUROSCIENCE, 2019, 13
  • [44] Feminizing gender-affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks
    Sudhakar, Deepshika
    Huang, Zhong
    Zietkowski, Maeson
    Powell, Natasha
    Fisher, Andrew R.
    NEUROUROLOGY AND URODYNAMICS, 2023, 42 (05) : 903 - 920
  • [45] The Link between Estradiol and Neuroplasticity in Transgender Women after Gender-Affirming Surgery: A Bimodal Hypothesis
    Schneider, Maiko A.
    Spritzer, Poli M.
    Suh, Jee Su
    Minuzzi, Luciano
    Frey, Benicio N.
    Schwarz, Karine
    Costa, Angelo B.
    da Silva, Dhiordan C.
    Garcia, Claudia C. G.
    Fontanari, Anna M., V
    Anes, Mauricio
    Castan, Juliana U.
    Cunegatto, Fernanda R.
    Picon, Felipe A.
    Luders, Eileen
    Lobato, Maria I. R.
    NEUROENDOCRINOLOGY, 2020, 110 (06) : 489 - 500
  • [46] Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review
    Spanos, Cassandra
    Bretherton, Ingrid
    Zajac, Jeffrey D.
    Cheung, Ada S.
    WORLD JOURNAL OF DIABETES, 2020, 11 (03) : 66 - 77
  • [47] Transgender and Nonbinary Individuals' Perceptions Regarding Gender-Affirming Hormone Therapy and Cardiovascular Health: A Qualitative Study
    Rytz, Chantal L.
    Pattar, Badal S. B.
    Mizen, Sara J.
    Lieb, Parker
    Parsons Leigh, Jeanna
    Saad, Nathalie
    Dumanski, Sandra M.
    Beach, Lauren B.
    Marshall, Zack
    Newbert, Amelia M.
    Peace, Lindsay
    Ahmed, Sofia B.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2024, 17 (09):
  • [48] Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment
    Dobrolinska, Magdalena
    van der Tuuk, Karin
    Vink, Patti
    van den Berg, Marjan
    Schuringa, Anke
    Monroy-Gonzalez, Andrea G.
    Garcia, David Vallez
    Schultz, Willibrord C. M. Weijmar
    Slart, Riemer H. J. A.
    JOURNAL OF SEXUAL MEDICINE, 2019, 16 (09) : 1469 - 1477
  • [49] Sperm quality in transgender women before or after gender affirming hormone therapy-A prospective cohort study
    Rodriguez-Wallberg, Kenny A.
    Haljestig, Jakob
    Arver, Stefan
    Johansson, Anna L., V
    Lundberg, Frida E.
    ANDROLOGY, 2021, 9 (06) : 1773 - 1780
  • [50] Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults
    Iwamoto, Sean J.
    Defreyne, Justine
    Kaoutzanis, Christodoulos
    Davies, Robert D.
    Moreau, Kerrie L.
    Rothman, Micol S.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2023, 14